Johnson & Johnson has reported 2024 second quarter sales growth of 4.3 percent to $22.4 billion, with operational growth of 6.6 percent. Reported second quarter sales in the U.S. totaled $12.6 billion, a 7.8 percent increase over the same period last year, the company announced. “Johnson & Johnson’s second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth. With a robust pipeline, upcoming regulatory milestones for Rybrevant and Tremfya, the integration of Shockwave, and continued expansion of newly launched products, including Acuvue Oasys Max 1-Day contact lenses and our Varipulse platform, we have a strong foundation for near and long-term growth” said Joaquin Duato, Chairman and Ceo. The company also increased its full-year 2024 operational sales guidance to reflect the acquisition of Shockwave Medical. Operational sales for full-year 2024 are now expected to be in the range of $89.2 billion to $89.6 billion compared with $88.7 billion to $89.1 billion in April 2024.

August 2024